UNI-EN 132:Treasury shares
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 132 | / | 2018 | |||||||
Date of issue: | 2018-11-01 | ||||||||||
Short name of the issuer | |||||||||||
SOPHARMA AD | |||||||||||
Subject | |||||||||||
Treasury shares | |||||||||||
Official market - legal basis | |||||||||||
art. 56. 1. 2 of Act on Public Offering. | |||||||||||
Unofficial market - legal basis | |||||||||||
Contents of the report: | |||||||||||
Sopharma AD (3JR: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that on October 31, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 500 own shares representing 0.0004% of the capital of the Company. The total number of treasury shares after this transfer is 8 836 366, representing 6.56% of the share capital of the Company. | |||||||||||
Annexes | |||||||||||
File | Description | ||||||||||
Current report 132 buy back 31102018 espi.pdf Current report 132 buy back 31102018 espi.pdf |
SOPHARMA AD | |||||||||||||
(fullname of the issuer) | |||||||||||||
SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
(short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
1220 | Sofia | ||||||||||||
(post code) | (city) | ||||||||||||
IlienskoShosse | 16 | ||||||||||||
(street) | (number) | ||||||||||||
+359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
(phone number) | (fax) | ||||||||||||
(e-mail) | (web site) | ||||||||||||
nd | |||||||||||||
(NIP) | (REGON) |
SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
Date | Name | Position / Function | Signature | ||
2018-11-01 | Ognian Donev | Executive director |
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 9.1 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.